Evaluation of serum arginase activity in benign prostatic hypertrophy and prostatic cancer

ELGÜN ÜLKAR S., Keskineǧe A., YILMAZ E., BALTACI S., Bedük Y.

International Urology and Nephrology, cilt.31, sa.1, ss.95-99, 1999 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 31 Sayı: 1
  • Basım Tarihi: 1999
  • Doi Numarası: 10.1023/a:1007132109061
  • Dergi Adı: International Urology and Nephrology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.95-99
  • Ankara Üniversitesi Adresli: Evet

Özet

Activities of arginase, prostatic acid phosphatase (PAP) and prostate specific antigen (PSA) were determined in sera of healthy male controls, benign prostatic hypertrophy (BPH) and prostatic cancer patients. Serum arginase activity in the cancer group (22.8±11.6 U/l) was significantly lower than in both the control (33.64±16.19 U/l) and the BPH group (58.8±11.6 U/l) (p<0.001, respectively), while the BPH group had significantly higher levels compared to the controls (p<0.05). However, serum arginase levels in all groups had no statistically significant correlation with PAP and PSA. Serum arginase activity correlated inversely with the Gleason grades. These results suggest that serum arginase assay may be used for the pretreatment evaluation of patients with prostatic diseases.